Cytotron: Exciting New Development

One of the most popular posts on my blog has been Cytotron : A cure for Arthritis ?? . Many have wondered when would this pathbreaking technology become mainstream and be available in the US.

Now there's some exciting news on that front:  "The CYTOTRON  is a Rotational Field Quantum Magnetic Resonance device to treat cancer and improve drug targeting and delivery... Shréis Scalene Sciences LLC, an Organization de Scalene member company, today announced that it has been awarded a cash grant of about a quarter million USD, under the U.S. Government’s Qualifying Therapeutic Discovery Project (“QTDP”) program, for 2010 "

The grant has been awarded to Shréis Scalene Sciences LLC (USA) to use "the CYTOTRON, as a stand-alone device utilizing Rotational Field Quantum Magnetic Resonance (RFQMR) to treat cancer and improve drug targeting and delivery through nano-permeabilization”.

The device uses Rotational Field Quantum Nuclear Magnetic Resonance (RFQMR) to deliver highly complex quantum (packet switched) beams in radiofrequency (RF) bands and harmonics ranging up to 300MHz in the presence of high instantaneous magnetic fields between 1mT to 6T, with specialized near field parabolic antennae.

Despite the wide array of prevailing therapies covering the entire range of the EM spectrum - from minimally invasive (thermal) RF ablation to complex ionizing radiation/prohibitive proton beam therapies - there is no stand alone, whole body, multi-organ suitable therapeutic device on the market today.

The CYTOTRON uniquely combines RF with instantaneous NMR, to safely yet effectively perform in vivo multi organ tissue engineering, with minimal/no collateral damage. A clinical trial was also registered with clinicaltrials.gov (NCT01220830) using the CYTOTRON to treat Multiple Sclerosis. The trial is ongoing at the S-CARD campus in Bangalore.

An international patent application filed by the inventor Dr. Rajah Vijay Kumar, for the use of a Cytotron application called Focused Resonance Nano-permeabilization (FORN) has been recently published by the World Intellectual Property Organization (WIPO). Evidence exists that FORN can be combined with chemotherapy, using it as a "drug focusing and delivery tool" to non-invasively target intractable, impervious lesions, helping to reduce systemic toxicities and improve therapeutic windows.

Thomas Jefferson Hospital in Philadelphia (PA) has issued a letter of intent to conduct a clinical trial using the Cytotron in brain cancer. Early interest was received from the Center for Prostate Disease Research-WRAMC for the use of the Cytotron to treat prostate cancer. SSS executives are confident that the award of the prestigious QTDP grant will open up more doors to make the device and the treatment available in multiple medical institutions nationwide.

Read more details at : Shréis Scalene awarded Federal QTDP grant to advance use of the CYTOTRON